Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Closely watched Pfizer lung cancer drug falls short in clinical trial

Pfizer's $43B Seagen acquisition shows cracks as sigvotatug vedotin fails to replace docetaxel in lung cancer trials. The failure highlights M&A execution risk, revealing how integration challenges can erode clinical pipelines and shareholder confidence in acquisition-driven growth.